Organo Corporation
Organo Corporation (ORGJF) Financial Performance & Income Statement Overview
Review Organo Corporation (ORGJF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Organo Corporation (ORGJF) Income Statement & Financial Overview
View the income breakdown for Organo Corporation ORGJF across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $47.57B | $41.38B | $42.70B | $31.62B |
| Cost of Revenue | $29.65B | $27.26B | $29.42B | $21.76B |
| Gross Profit | $17.92B | $14.12B | $13.28B | $9.86B |
| Gross Profit Ratio | $0.38 | $0.34 | $0.31 | $0.31 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $6.55B | $5.85B | $5.80B | $5.86B |
| Operating Expenses | $6.55B | $5.85B | $5.80B | $5.86B |
| Total Costs & Expenses | $36.20B | $33.11B | $35.23B | $27.62B |
| Interest Income | $23.00M | $37.00M | $34.00M | $26.00M |
| Interest Expense | $61.00M | $57.00M | $63.00M | $65.00M |
| Depreciation & Amortization | $583.00M | $502.50M | $445.00M | $502.50M |
| EBITDA | $12.35B | $8.77B | $8.08B | $4.86B |
| EBITDA Ratio | $0.26 | $0.21 | $0.19 | $0.15 |
| Operating Income | $11.37B | $8.27B | $7.48B | $4.001B |
| Operating Income Ratio | $0.24 | $0.20 | $0.18 | $0.13 |
| Other Income/Expenses (Net) | $325.00M | -$272.00M | $814.00M | $371.00M |
| Income Before Tax | $11.70B | $7.99B | $8.29B | $4.37B |
| Income Before Tax Ratio | $0.25 | $0.19 | $0.19 | $0.14 |
| Income Tax Expense | $1.50B | $2.15B | $2.83B | $1.69B |
| Net Income | $10.18B | $5.83B | $5.46B | $2.68B |
| Net Income Ratio | $0.21 | $0.14 | $0.13 | $0.08 |
| EPS | $221.58 | $126.82 | $118.70 | $58.24 |
| Diluted EPS | $221.58 | $126.82 | $118.70 | $58.24 |
| Weighted Avg Shares Outstanding | $45.97M | $45.98M | $45.98M | $45.94M |
| Weighted Avg Shares Outstanding (Diluted) | $45.97M | $45.98M | $45.98M | $45.94M |
The company's financials show resilient growth, with revenue advancing from $31.62B in Q1 2024 to $47.57B in Q4 2024. Gross profit remained healthy with margins at 38% in Q4 2024 compared to 31% in Q1 2024. Operating income hit $11.37B last quarter, sustaining a consistent 24% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $12.35B. Net income rose to $10.18B, while earnings per share reached $221.58. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan